ASCO 2021: Addition of Abiraterone to Standard of Care Improved Radiographic Progression-Free Survival in Metastatic Prostate Cancer
Author suggests abiraterone-prednisone should be part of standard of care in de novo metastatic prostate cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.